New drug shows promise in taming dangerous blood fats

NCT ID NCT04998201

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether an experimental drug called plozasiran (ARO-APOC3) could safely and effectively lower unhealthy levels of fats and cholesterol in the blood, a condition called mixed dyslipidemia. Over 350 adults already on standard cholesterol medication were randomly assigned to receive either the drug or a placebo for 48 weeks while following a recommended diet. The main goal was to see how much the drug reduced a specific type of fat (triglycerides) after 24 weeks and to monitor safety throughout the study.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site 1

Fort Lauderdale, Florida, 33308, United States
Research Site 10

Montreal, Quebec, H2W2T2, Canada
Research Site 11

Auckland, 2025, New Zealand
Research Site 12

Dayton, Ohio, 45419, United States
Research Site 13

San Antonio, Texas, 78249, United States
Research Site 14

Miami Springs, Florida, 33166, United States
Research Site 15

Concord, Ontario, L4K 4M2, Canada
Research Site 16

Christchurch, 8013, New Zealand
Research Site 17

New Windsor, New York, 12553, United States
Research Site 18

Dunwoody, Georgia, 30338, United States
Research Site 19

Clayton, Victoria, 3168, Australia
Research Site 2

Boca Raton, Florida, 33434, United States
Research Site 20

Balatonfüred, H-8230, Hungary
Research Site 21

Debrecen, H-4032, Hungary
Research Site 22

Nyíregyháza, H-4405, Hungary
Research Site 24

Lodz, 94-048, Poland
Research Site 25

Poznan, 61-655, Poland
Research Site 26

Rzeszów, 35-055, Poland
Research Site 27

Joondalup, Western Australia, 6027, Australia
Research Site 28

Lodz, 93-338, Poland
Research Site 29

Adelaide, South Australia, 5000, Australia
Research Site 3

Beverly Hills, California, 90211, United States
Research Site 30

Morayfield, Queensland, 4506, Australia
Research Site 31

Las Vegas, Nevada, 89121, United States
Research Site 32

Houston, Texas, 77030, United States
Research Site 4

Franklin, Ohio, 45005, United States
Research Site 5

Pembroke Pines, Florida, 33024, United States
Research Site 6

Houston, Texas, 77002, United States
Research Site 7

Greenville, South Carolina, 29607, United States
Research Site 8

Northridge, California, 91325, United States

Conditions

Explore the condition pages connected to this study.

MIXED DYSLIPIDEMIA